Recruiting

Telehealth Genetics

Sponsor:

Abramson Cancer Center at Penn Medicine

Code:

NCT07471958

Conditions

Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Study Details

Brief summary:

The purpose of the study is to understand patient interest in telehealth and digital tools for pre-test genetic education and/or disclosure of genetic test results. Participants will receive telehealth genetic counseling in the home and may be offered various digital tools to help with the counseling and testing process. These are optional and participants can still speak with a genetic counselor if they wish.

Conditions

Cancer

Study ID

NCT07471958

Start date

Sep 2, 2025

Status verified date

Mar, 2026

Completion date

Mar, 2029

Anticipated

Primary completion date

Mar, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • 18 years of age or older
  • Speak and understand English
  • Meet current National Comprehensive Cancer Network (NCCN) or other national guidelines for germline genetic testing or are interested in genetic counseling based on personal or family history of cancer. Patients with prior genetic testing are eligible if they meet criteria for updated testing, or if post-test genetic counseling services are requested.

Exclusion Criteria:

  • Communication difficulties such as:
  • Uncorrected or uncompensated hearing and/or vision impairment. Patients who can successfully use clinical assistance devices are not excluded.
  • Uncorrected or uncompensated speech defects. Patients who can successfully use clinical assistance devices are not excluded.
  • Uncontrolled psychiatric/mental condition or severe physical, neurological or cognitive deficits rendering individual unable to understand study goals and tasks

Study Design

Enrollment

360 participants

Anticipated

Interventions and Outcome Measures

Arms

Visit 1

All participants will be offered remote telehealth Visit 1 services by telephone or real-time videoconference or by a chatbot (patient choice).

Primary outcome measure

  • Uptake of Visit 1 [ Time Frame: Through 6 months ]
  • Uptake of Digital Visit 1 [ Time Frame: Through 6 months ]
  • Uptake of genetic testing [ Time Frame: Through 6 months ]

Central Contacts and Locations

Central contacts

Angela Bradbury, MD

215-615-3341angela.bradbury@pennmedicine.upenn.edu

Kelsey Karpink

215-662-3531kelsey.karpink@pennmedicine.upenn.edu

Locations

Abramson Cancer Center at the University of Pennsylvania

Recruiting

Philadelphia, Pennsylvania, United States, 19104

Contacts

Angela Bradbury, MD

215-615-3341angela.bradbury@pennmedicine.upenn.edu

More Information

Sponsor

Abramson Cancer Center at Penn Medicine

Last update posted

Mar 13, 2026

Last verified

Mar, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Abramson Cancer Center at Penn Medicine on 2026-03-13.